open in a new window Search Investors IR Home Events & Presentations Corporate Governance Financial Information Stock Information Investor FAQs Press Releases Investor Contacts Home › Investors NASDAQ: IRWD 11.58 -0.05 -0.43% Volume: 1,278,120 November 24, 2021 4:00 PM Pricing delayed by 20 minutes Click to learn more Corporate Overview At Ironwood, we're focused on delivering differentiated medicines to patients and generating outstanding returns for shareholders. If we do this efficiently and effectively, we hope to inspire continued support so that we can seek to develop and deliver more medicines for patients living with GI diseases. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders. Read More Featured Reports pdf Format Download (opens in new window) Form 10-Q November 04, 2021 pdf Format Download (opens in new window) Form 10-K February 17, 2021 pdf Format Download (opens in new window) Proxy Statement April 22, 2021 View All Results Featured Events November 4, 2021 08:30 AM ET Ironwood Pharmaceuticals 3Q 2021 Investor Update Call Listen to webcast (opens in new window) September 13, 2021 02:45 PM ET Morgan Stanley 19th Annual Global Healthcare Conference Listen to webcast (opens in new window) View All Events View All News Recent News showing 1-3 of 3 November 4, 2021 Title for Article. Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update November 4, 2021 Title for Article. Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. October 25, 2021 Title for Article. More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021 More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021 Corporate Presentation Ironwood Pharmaceuticals 3Q 2021 Investor Update Conference Call November 4, 2021 Download (opens in new window) (PDF 1.62 mb) Investor Alerts News Events & Presentations SEC Filings End of Day Stock Quote Quarterly Reports Annual Reports Submit Contact Us Matt Roache Director, Investor Relations 617.621.8395 MRoache@ironwoodpharma.com Auditors Ernst & Young 200 Clarendon Street Boston, MA 02116 617.266.2000 Transfer Agent Computershare Investor Services P.O. Box 30170 College Station, TX 77842 800.662.7232 www.computershare.com Our Company open in a new window Our Values open in a new window Our Executive Team open in a new window Our Board of Directors open in a new window Open Payments and Transparency open in a new window Our Product open in a new window Discovery of Linaclotide open in a new window Our Pipeline open in a new window Partnerships open in a new window Patients open in a new window Join Us open in a new window Open Positions open in a new window Things You Should Know open in a new window Investors Events & Presentations Corporate Governance Financial Information Stock Information Investor FAQ Press Releases Investor Contacts Media open in a new window Contact Us open in a new window Follow Us Linkedin open in a new window Twitter open in a new window Privacy Policy Terms of Use California Privacy Policy Site Map Contact Us Back To Top Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved. Powered By Q4 Inc. 5.56.0.1 (opens in new window)